tm2618428-1_424b5 - none

424B5 1 tm2618428-1_424b5.htm 424B5 tm2618428-1_424b5 - none - 5.9219077s

The information in this preliminary prospectus supplement is not complete and may be changed. This preliminary prospectus supplement and the accompanying prospectus are not an offer to sell these securities and they are not soliciting an offer to buy these securities in any jurisdiction where the offer or sale thereof is not permitted.

Filed pursuant to Rule 424(b)(5)

Registration No. 333-284168

Subject to completion, dated June 22, 2026

Preliminary prospectus supplement
(To prospectus dated January 7, 2025)

$150,000,000

Ordinary Shares
Pre-Funded Warrants to Purchase Ordinary Shares

We are offering ordinary shares, nominal value €0.05 per share, and, in lieu of ordinary shares to certain investors, pre-funded warrants to purchase ordinary shares pursuant to this prospectus supplement and the accompanying prospectus. The purchase price of each pre-funded warrant will equal the price per ordinary share at which our ordinary shares are being sold to the public in this offering, minus $0.0001, which is the exercise price of each pre-funded warrant. This prospectus supplement also relates to the offering of our ordinary shares issuable upon exercise of the pre-funded warrants.

Our ordinary shares are listed on The Nasdaq Global Select Market, or Nasdaq, under the symbol “QURE.” On June 22, 2026, the last reported sale price of our ordinary shares on Nasdaq was $44.39 per ordinary share. We do not intend to list the pre-funded warrants on Nasdaq, any other national securities exchange or any other nationally recognized trading system.

Investing in our ordinary shares or pre-funded warrants involves significant risks. See “Risk Factors” beginning on page S-7 of this prospectus supplement as well as the documents incorporated by reference into this prospectus supplement and the accompanying prospectus for a discussion of the factors you should consider before deciding to purchase our securities.

Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or passed upon the adequacy or accuracy of this prospectus supplement or the accompanying prospectus. Any representation to the contrary is a criminal offense.

Per ordinary
share

Per pre-funded
warrant

Total

Public offering price

Underwriting discounts and commissions(1)

Proceeds to uniQure N.V. (before expenses)

(1)

See “Underwriting” beginning on page S-29 of this prospectus supplement for additional information regarding total underwriting compensation.

Delivery of our ordinary shares and pre-funded warrants is expected to be made on or about June , 2026. We have granted the underwriters an option for a period of 30 days to purchase up to an additional ordinary shares at the public offering price less the underwriting discounts and commissions.

Bookrunning Managers

Leerink Partners

Stifel

The date of this prospectus supplement is June , 2026.

	Page
ABOUT THIS PROSPECTUS SUPPLEMENT		S-ii
SPECIAL CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS		S-iv
ENFORCEMENT OF CIVIL LIABILITIES		S-vi
PROSPECTUS SUPPLEMENT SUMMARY		S-1
THE OFFERING		S-5
RISK FACTORS		S-7
USE OF PROCEEDS		S-12
DIVIDEND POLICY		S-13
DILUTION		S-14
DESCRIPTION OF PRE-FUNDED WARRANTS		S-16
MATERIAL DUTCH AND U.S. FEDERAL INCOME TAX CONSIDERATIONS		S-18
UNDERWRITING		S-29
LEGAL MATTERS		S-35
EXPERTS		S-36
WHERE YOU CAN FIND MORE INFORMATION		S-37
INCORPORATION OF CERTAIN INFORMATION BY REFERENCE		S-38

	Page
ABOUT THIS PROSPECTUS		1
THE COMPANY		2
RISK FACTORS		3
SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS		4
USE OF PROCEEDS		6
DESCRIPTION OF ORDINARY SHARES AND ARTICLES OF ASSOCIATION		7
DESCRIPTION OF DEBT SECURITIES		13
DESCRIPTION OF WARRANTS		19
DESCRIPTION OF RIGHTS		20
DESCRIPTION OF UNITS		21
CONVERTIBLE OR EXCHANGEABLE SECURITIES		22
FORM, EXCHANGE AND TRANSFER		23
BOOK-ENTRY PROCEDURES AND SETTLEMENT		24
PLAN OF DISTRIBUTION		26
LEGAL MATTERS		29
EXPERTS		30
WHERE YOU CAN FIND MORE INFORMATION		31
INCORPORATION OF CERTAIN INFORMATION BY REFERENCE		32

Public offering price per ordinary share			$
Net tangible book value per ordinary share as of March 31, 2026	$	0.74
Increase per ordinary share attributable to new investors
As adjusted net tangible book value per ordinary share as of March 31, 2026 after giving effect to this offering
Dilution per ordinary share to new investors purchasing ordinary shares in this offering			$